Prolongation of the Interval Between Prothrombin Time Tests in Stable Patients II (PRINT-II)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01654042|
Recruitment Status : Withdrawn (No funding obtained)
First Posted : July 31, 2012
Last Update Posted : March 20, 2014
Information provided by (Responsible Party):
Sam Schulman, McMaster University
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
|Recruitment Status :||Withdrawn|
|Estimated Primary Completion Date :||April 2018|
|Estimated Study Completion Date :||October 2018|
Schulman S, Parpia S, Stewart C, Rudd-Scott L, Julian JA, Levine M. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med. 2011 Nov 15;155(10):653-9, W201-3. doi: 10.7326/0003-4819-155-10-201111150-00003.